ReviewJournal of biosciences2021
Nutraceutical and therapeutic potential of Phycocyanobilin for treating Alzheimer's disease.
Review in Journal of biosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- RAGE Axis in the Pathogenesis and Treatment of CNS Neurodegeneration in Long-Term Hyperglycemia.International journal of molecular sciences · 2026Review
- Article
- Production and Applications of Cyanobacterial Phycocyanin: Trends and Prospects.Indian journal of microbiology · 2025Article
- Microalgae and exercise: from molecular mechanisms and brain health to clinical perspectives in the context of 3P medicine.The EPMA journal · 2025Review
- Optimization of Phycocyanobilin Synthesis inGenes · 2024Article
- Natural Pigments Recovery from Food By-Products: Health Benefits towards the Food Industry.Foods (Basel, Switzerland) · 2024Review
- Review
- Rational Design of Key Enzymes to Efficiently Synthesize Phycocyanobilin inBiomolecules · 2024Article
- Progress on the Extraction, Separation, Biological Activity, and Delivery of Natural Plant Pigments.Molecules (Basel, Switzerland) · 2023Review
- Beneficial Effects of Spirulina Consumption on Brain Health.Nutrients · 2022Review
- The Effect of C-Phycocyanin on Microglia Activation Is Mediated by Toll-like Receptor 4.International journal of molecular sciences · 2022Article
- The Bioactivities of Phycocyanobilin from Spirulina.Journal of immunology research · 2022Review
- Phycobiliproteins: Structural aspects, functional characteristics, and biotechnological perspectives.Computational and structural biotechnology journal · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a devastating neurodegenerative condition provoking the loss of cognitive and memory performances. Despite huge efforts to develop effective AD therapies, there is still no cure for this neurological condition. Here, we review the main biological properties of Phycocyanobilin (PCB), accounting for its potential uses against AD. PCB, given individually or released in vivo from C-Phycocyanin (C-PC), acts as a bioactive-molecule-mediating antioxidant, is anti-inflammatory and has immunomodulatory activities. PCB/C-PC are able to scavenge reactive oxygen and nitrogen species, to counteract lipid peroxidation and to inhibit enzymes such as NADPH oxidase and COX-2. In animal models of multiple sclerosis and ischemic stroke, these compounds induce remyelination as demonstrated by electron microscopy and the expression of genes such as
Indexed as
Identifiers
34047285W3157468877What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.